Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Beta Bionics in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-323777
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(45,298) | $(45,525) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 1,294 | 650 |
| Provision for expected credit losses | 16 | — |
| Stock-based compensation expense | 12,422 | 7,603 |
| Net provision (recovery) for excess and obsolete inventory | (179) | 347 |
| Change in fair value of warrant liabilities | — | 12,450 |
Item 1. Financial Statements.
FAQ
- What is Beta Bionics's D&A?
- Beta Bionics (BBNX) reported D&A of $709K in Q2 2026.
- How has Beta Bionics's D&A changed year-over-year?
- Beta Bionics's D&A increased by 104.3% year-over-year, from $347K to $709K.
- What is the long-term trend for Beta Bionics's D&A?
- Over 2 years (2023 to 2025), Beta Bionics's D&A has grown at a 13.3% compound annual growth rate (CAGR), from $1.23M to $1.57M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Beta Bionics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude